An interesting study reported the results of 80 PD-L1-negative cervical cancer patients treated with a TIL and anti-PD-1 combination therapy; the objective response was observed in 20 patients (25%), and the authors speculated that TILs penetrated the tumor microenvironment and secreted factors, which induced the expression of PD-L1 in the tumor cells [55]. The gene discussed is CD274; the disease is cervical carcinoma.